Wegovy's revenue jumped by 86% year over year to 58.2 billion DKK ($8.1 billion). It's no wonder Novo Nordisk's shares jumped following the release of its fourth-quarter and full-year 2024 ...
Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...
Novo Nordisk’s shares rose by as much as 14% during Friday’s trading before paring gains to close 7.13% higher in Copenhagen. Meanwhile, Eli Lilly’s stocks dipped 1.2% at the US market open ...
16.2% on 5 mg after 28 weeks and 22% on 20 mg after 36 weeks. The figures come from an analysis that assessed the effect of amycretin if all people adhered to treatment. Novo made no mention of ...
Novo Nordisk A/S rose the most since August 2023 ... while rival Eli Lilly & Co.’s fell 1.2% before US markets opened.
Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing ... with the more common type 2 diabetes. Minnesota's case began ...
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...
PAUL (Valley News Live) - Attorney General Keith Ellison announced a settlement with Novo Nordisk that guarantees ... per monthly prescription (3 vials or 2 packs of pens) for customers paying ...
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...
Novo Nordisk estimates that around 40% of people with type 2 diabetes have chronic kidney disease, which affects about 37 million adults in the United States. Last year, the FDA had approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback